WO2002099421A3 - Specific microarrays for breast cancer screening - Google Patents

Specific microarrays for breast cancer screening Download PDF

Info

Publication number
WO2002099421A3
WO2002099421A3 PCT/US2002/016038 US0216038W WO02099421A3 WO 2002099421 A3 WO2002099421 A3 WO 2002099421A3 US 0216038 W US0216038 W US 0216038W WO 02099421 A3 WO02099421 A3 WO 02099421A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
specific
cancer screening
microarrays
specific microarrays
Prior art date
Application number
PCT/US2002/016038
Other languages
French (fr)
Other versions
WO2002099421A2 (en
Inventor
Edward Sauter
Garrett Dubois
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of WO2002099421A2 publication Critical patent/WO2002099421A2/en
Publication of WO2002099421A3 publication Critical patent/WO2002099421A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Microarrays specific for breast cancer are provided. Also provided are methods for detecting breast cancer in patients or screening therapeutics for the treatment or prevention of breast cancer by analyzing expression levels of specific genes in BECs or quantifying specific protein levels in breast ductal fluid.
PCT/US2002/016038 2001-05-18 2002-05-20 Specific microarrays for breast cancer screening WO2002099421A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29214901P 2001-05-18 2001-05-18
US60/292,149 2001-05-18
US34032001P 2001-12-14 2001-12-14
US34015301P 2001-12-14 2001-12-14
US60/340,153 2001-12-14
US60/340,320 2001-12-14

Publications (2)

Publication Number Publication Date
WO2002099421A2 WO2002099421A2 (en) 2002-12-12
WO2002099421A3 true WO2002099421A3 (en) 2003-12-18

Family

ID=27404109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016038 WO2002099421A2 (en) 2001-05-18 2002-05-20 Specific microarrays for breast cancer screening

Country Status (1)

Country Link
WO (1) WO2002099421A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228709A1 (en) * 2002-03-25 2003-12-11 Kozlowski Roland Zbignieiw Arrays
ES2504242T3 (en) * 2004-02-20 2014-10-08 Janssen Diagnostics, Llc Breast Cancer Prognosis
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BERTUCCI F ET AL: "Gene expression profiling of primary breast carcinomas using arrays of cancidate genes", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 20, 2000, pages 2981 - 2991, XP002225994, ISSN: 0964-6906 *
BRENTON J D ET AL: "Molecular profiling of breast cancer: portraits but not physiognomy.", BREAST CANCER RESEARCH: BCR. ENGLAND 2001, vol. 3, no. 2, 2001, pages 77 - 80, XP009012575, ISSN: 1465-5411 *
KARI F W ET AL: "Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction.", THE JOURNAL OF NUTRITION, HEALTH & AGING. FRANCE 1999, vol. 3, no. 2, 1999, pages 92 - 101, XP001147671, ISSN: 1279-7707 *
LAKHANI S R ET AL: "Profiling familial breast cancer.", NATURE MEDICINE. UNITED STATES APR 2001, vol. 7, no. 4, April 2001 (2001-04-01), pages 408 - 410, XP001153021, ISSN: 1078-8956 *
LEE A V ET AL: "IGF system components as prognostic markers in breast cancer.", BREAST CANCER RESEARCH AND TREATMENT. NETHERLANDS FEB 1998, vol. 47, no. 3, February 1998 (1998-02-01), pages 295 - 302, XP009012579, ISSN: 0167-6806 *
MARTIN K J ET AL: "A HYBRIDIZATION ARRAY ASSAY USING DIFFERENTIAL DISPLAY-IDENTIFIED MARKERS FOR EARLY DETECTION AND STAGING OF BREAST CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 40, 10 April 1999 (1999-04-10), pages 319, XP001026342, ISSN: 0197-016X *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
MARTIN KATHERINE J ET AL: "High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2646 - 2651, XP002188522, ISSN: 0027-8424 *
NACHT MARIANA ET AL: "Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5464 - 5470, XP002166291, ISSN: 0008-5472 *
OSIN P ET AL: "EXPERIMENTAL PATHOLOGY AND BREAST CANCER GENETICS: NEW TECHNOLOGIES", RECENT RESULTS IN CANCER RESEARCH, SPRINGER, BERLIN,, DE, vol. 152, 1998, pages 35 - 48, XP008015152, ISSN: 0080-0015 *
UNGER M A ET AL: "Recent advances in breast cancer biology.", CURRENT OPINION IN ONCOLOGY. UNITED STATES NOV 2000, vol. 12, no. 6, November 2000 (2000-11-01), pages 521 - 525, XP009012574, ISSN: 1040-8746 *
ZHANG G J ET AL: "The role of bcl-2 expression in breast carcinomas (Review).", ONCOLOGY REPORTS. GREECE 1998 SEP-OCT, vol. 5, no. 5, September 1998 (1998-09-01), pages 1211 - 1216, XP009012601, ISSN: 1021-335X *

Also Published As

Publication number Publication date
WO2002099421A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
HK1148783A1 (en) Gene expression markers for breast cancer prognosis
WO2005084109A3 (en) Cancer specific gene mh15
HK1120567A1 (en) Gene expression profiling in biopsied tumor tissues
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2003087831A3 (en) Proteins involved in breast cancer
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2006037462A3 (en) Cancer markers
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2009087462A3 (en) Ephrin type-a receptor 10 protein
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
DE60137264D1 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
AU3392901A (en) Proteins
WO2002099421A3 (en) Specific microarrays for breast cancer screening
WO2004040312A3 (en) Method for ngf assay for in vitro diagnosis of breast cancer and therapeutic use
MXPA05006034A (en) Replication protein.
WO2005106039A8 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
HK1090392A1 (en) Methods for the diagnosis and prognosis of alzheimers disease
WO2002086084A3 (en) Sequence characteristics of bladder cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP